Roche’s Columvi pass­es Phase 3 lym­phoma test as com­pe­ti­tion with Ab­b­Vie, Gen­mab con­tin­ues

Roche’s Columvi is on the path to a full ap­proval and po­ten­tial­ly a la­bel ex­pan­sion in an ear­li­er lym­phoma set­ting af­ter hit­ting the pri­ma­ry end­point of a late-stage tri­al.

The CD20xCD3 bis­pe­cif­ic an­ti­body al­ready won FDA ac­cel­er­at­ed ap­proval for re­lapsed or re­frac­to­ry dif­fuse large B-cell lym­phoma (DL­B­CL) af­ter two or more lines of ther­a­py in June 2023.

The con­fir­ma­to­ry Phase 3 STAR­G­LO study com­pared Columvi plus gem­c­itabine and ox­ali­platin (GemOx) ver­sus rit­ux­imab plus GemOx in DL­B­CL pa­tients who have had at least one pri­or line of ther­a­py and are not el­i­gi­ble for au­tol­o­gous stem cell trans­plant. Columvi met the tri­al’s pri­ma­ry end­point, achiev­ing a “sta­tis­ti­cal­ly sig­nif­i­cant” im­prove­ment in over­all sur­vival ver­sus con­trol, per a Mon­day re­lease, al­though de­tails were lim­it­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER